June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Incidence, Clinical Features, and Visual Outcomes of Endophthalmitis Following Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Medications
Author Affiliations & Notes
  • Jared Moon
    Ophthalmology, Austin Retina Associates, The University of Texas at Austin Dell Medical School, Austin, Texas, United States
  • Saima Khan
    Ophthalmology, Austin Retina Associates, The University of Texas at Austin Dell Medical School, Austin, Texas, United States
  • Caroline Rosanky
    Ophthalmology, Austin Retina Associates, The University of Texas at Austin Dell Medical School, Austin, Texas, United States
  • Philip P Storey
    Ophthalmology, Austin Retina Associates, The University of Texas at Austin Dell Medical School, Austin, Texas, United States
  • Footnotes
    Commercial Relationships   Jared Moon None; Saima Khan None; Caroline Rosanky None; Philip Storey None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3934. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jared Moon, Saima Khan, Caroline Rosanky, Philip P Storey; Incidence, Clinical Features, and Visual Outcomes of Endophthalmitis Following Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Medications. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3934.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the incidence, clinical features, and outcomes of patients who developed endophthalmitis following intravitreal Injection (IVI) of anti-vascular endothelial growth factor medications.

Methods : Data was collected from all patients who developed post-IVI endophthalmitis from March 2015 to November 2022 at Austin Retina Associates. Visual acuity (VA) outcomes were evaluated at 3 and 6-months post-infection.

Results : A total of 249,117 intravitreal injections and 73 post-IVI endophthalmitis patients were included, giving an overall infection rate of 1 in 2954 injections (0.025%). Average patient age was 74.1 years (range 29-95) and 61.9% were female. Patients received an average of 19.5 IVIs prior to development of endophthalmitis (range 1-70). Patients presented an average of 3.2 days after IVI. Visual acuity returned to baseline or improved for 28 patients (44.4%) at 3-months and 29 patients (46.0% at 6-months). Rates of endophthalmitis were 1 in 5439 (0.018%) for bevacizumab, 1 in 6316 (0.016%) for ranibizumab, and 1 in 3273 (0.031%) for aflibercept with no significant difference found between medications (p=0.15). No significant differences in 3-month visual outcomes were found between medications (p=0.42), age at time of injection (p=0.53), number of prior injections (p=0.48), or time to presentation (p=0.77).

Conclusions : Endophthalmitis is a rare but potentially devastating complication of intravitreal injection and occurs after approximately 1 in 2954 injections. No difference in rates of infection were found between medications and no specific clinical features correlated with clinical outcomes.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×